- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01141855
Smoking Termination Opportunity for inPatients (STOP)
Effectiveness of Inpatient Initiated Varenicline Tartrate for Smoking Cessation, for Smoking Related Illnesses.
The Smoking Termination Opportunity for inPatients, (STOP) project is designed to capture the opportunity that is provided by admission for acute smoking related illness, to assist patients through withdrawal by use of a combination of:
- the new medication Champix with
- best practice counselling
- initiated in an inpatient setting
to achieve:
- sustained smoking abstinence
- reduced hospital bed and health service utilisation
- reduced inpatient smoking and craving prior to discharge
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
A national standard in public hospitals for the management of smoking in patients admitted with smoking related acute illnesses is lacking. Where such patients have continued to smoke up until the time of admission, it can be assumed that "primary" prevention has failed.
Once admitted, there is a vastly under-utilised opportunity, by use of a structured and systematic approach, to intervene with a secondary prevention attempt. This takes advantage of the synergy of:
- the smoker is a "captive audience" and may be receptive to considering lifestyle factors that have lead to the admission, and
- best practice medication and counselling can be initiated prior to discharge. If proven to be cost-effective in our analysis, a systematic roll-out of this secondary prevention initiative would be advocated. ie translation of research into practice.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
South Australia
-
Adelaide, South Australia, Austrálie, 5000
- Royal Adelaide Hospital
-
Adelaide, South Australia, Austrálie, 5011
- The Queen Elizabeth Hospital
-
Adelaide, South Australia, Austrálie, 5112
- Lyell McEwin Health Service
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Smoker of at least 10 cigarettes per day on average over the past 12 months
- Inpatient with an anticipation admission of at least one day
- Willingness to quit smoking
- Aged between 20 and 75 years
- A plan of discharge to go home
- Acute hospital admission with cardiovascular, cerebrovascular, peripheral vascular diseases or airways (asthma and/or Chronic Obstructive Pulmonary disease
Exclusion Criteria:
- Subject preference to use an alternative pharmacotherapy for smoking cessation
- Respiratory patient being considered for home oxygen
- Pregnancy
- Breast feeding
- Acute or pre-existing severe psychiatric illnesses
- Past history of psychosis or suicidal ideation
- Renal impairment with creatinine clearance <30ml/min
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Champix plus counselling
varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration).
In combination with Quit SA (5A) telephone counselling service
|
Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days 1mb b.d. for 70 days (full course 3 months)
Ostatní jména:
|
|
Aktivní komparátor: counselling alone
5A counselling via Quit SA (quitline) telephone counselling service.
(maximum 8 phone calls per subject within a 3 month period).
|
Quit SA 5A counselling over the phone.
Maximum 8 calls over a 3 month period
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Smoking abstinence
Časové okno: one year
|
Continued smoking abstinence is defined as: less than or equal to no more than 5 cigarettes smoked during the period of 2 weeks to 12 months post enrollment.
|
one year
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Reduced hospital bed utilisation
Časové okno: one year
|
Hospital casemix/DRG data will be collected for the 5 years prior to enrollment and one year post enrollment.
This will be supplemented by SA Department of Health data and PBS/MBS data sets of study completion, to monitor admissions at other hospitals and GP visits.
|
one year
|
|
7-day point prevalence
Časové okno: from 2 weeks to 3 months post enrollment
|
Defined as no cigarettes for the previous 7 days
|
from 2 weeks to 3 months post enrollment
|
|
Reduction in health care costs
Časové okno: one year
|
Reduced health care costs with greater economic value will be relative to other health interventions.
Four seperate economic models will be built for vascular diseases: cardiovascular, cerebrovascular and peripheral vascular diseases and airways diseases: asthma and/or chronic obstructive pulmonary disease.
Each model will compare outcomes and costs for varenicline and counselling compared to counselling alone, and will incorporate epidemiological data on natural disease progression of smokers and previous smokers from the four disease profiles split by gender if indicated.
|
one year
|
|
Inpatient craving levels
Časové okno: baseline to end of inpatient stay
|
Craving scales will be used to assess levels during inpatient stay (pre and post intervention delivery)
|
baseline to end of inpatient stay
|
|
Prevalence of inpatient smoking
Časové okno: From baseline to end of inpatient stay
|
Measured by self-report and observation by hospital and study staff prior to discharge.
|
From baseline to end of inpatient stay
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Brian J Smith, MBBS; FRACP;PhD;Dip Clin Epid, The Queen Elizabeth Hospital
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2008012
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .